RT Journal Article
SR Electronic
T1 SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20202846
DO 10.1101/2020.09.29.20202846
A1 O’Nions, J.
A1 Muir, L.
A1 Zheng, J.
A1 Rees-Spear, C.
A1 Rosa, A.
A1 Earl, C.
A1 Cherepanov, P.
A1 Gupta, R.
A1 Khwaja, A.
A1 Jolly, C.
A1 McCoy, L.E.
YR 2020
UL http://medrxiv.org/content/early/2020/10/01/2020.09.29.20202846.abstract
AB The development of antibody responses to SARS-CoV-2 is an indicator of seroprevalence and may afford protection from infection. It has been presumed that antibody responses to SARS-CoV-2 will be impaired in patients with aggressive haematological malignancy (PHM) due to underlying immunological dysfunction caused by malignancy or systemic anti-cancer treatment (SACT), placing them at increased risk. Here we analysed longitudinal serum samples from ten hospitalised PHM with aggressive disease and on SACT, collected up to 103 days post-onset of COVID-19 symptoms. We found that the majority (8/9) of PHM with confirmed SARS-CoV-2 infection seroconverted and developed antibodies to the major SARS-CoV-2 antigens (S1 and N) with most (6/8) produced neutralising antibody responses. Furthermore, the dynamics of antibody responses were broadly similar to that reported for the general population, except for a possible delay to seroconversion. Our finding that PHM on SACT can make functional antibody responses to SARS-CoV-2 has important implications for patient management and serological monitoring of SARS-CoV-2 in high-risk groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLEM and LM are supported by an MRC Career Development Award (MR/R008698/1) to LEM. CJ is supported by a Wellcome Trust Investigator award (108079/Z/15/Z). R.G. acknowledges funding from Cure Cancer@ UCL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical information was recorded and blood samples taken as routine standard of care. Patients were consented to allow any excess serum to be stored and used as part of the UCL Biobank for Studying Health and Disease, Haematology Project, reference no NC10.13, approved by the Leeds (East) Research Ethics Committee, UK.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon reasonable request.